Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Aya A. Negm"'
Autor:
Zuhier A. Awan, Shareefa A. AlGhamdi, Nabil A. Alhakamy, Solomon Z. Okbazghi, Mohamed A. Alfaleh, Shaimaa M. Badr-Eldin, Hibah M. Aldawsari, Mohammed A. S. Abourehab, Hani Z. Asfour, Shadi A. Zakai, Mohammad W. Alrabia, Aya A. Negm, Mohamed A. El-Moselhy, Sara S. Sharkawi, Waleed Y. Rizg
Publikováno v:
Drug Delivery, Vol 29, Iss 1, Pp 1536-1548 (2022)
Certain anticancer agents selectively target the nucleus of cancer cells. One such drug is 2-methoxyestradiol (2ME), which is used for treating lung cancer. To improve the therapeutic effectiveness of these agents, many new methods have been devised.
Externí odkaz:
https://doaj.org/article/ce92aa38c6d1400f8f34cfe349340dab
Autor:
Usama A. Fahmy, Shaimaa M. Badr-Eldin, Osama A. A. Ahmed, Hibah M. Aldawsari, Singkome Tima, Hani Z. Asfour, Mohammed W. Al-Rabia, Aya A. Negm, Muhammad H. Sultan, Osama A. A. Madkhali, Nabil A. Alhakamy
Publikováno v:
Pharmaceutics, Vol 16, Iss 2, p 189 (2024)
This journal retracts the article “Intranasal Niosomal In Situ Gel as a Promising Approach for Enhancing Flibanserin Bioavailability and Brain Delivery: In Vitro Optimization and Ex Vivo/In Vivo Evaluation” [...]
Externí odkaz:
https://doaj.org/article/08231fa9b9684763acc2045a7e8d8c0f
Autor:
Usama A. Fahmy, Shaimaa M. Badr-Eldin, Osama A. A. Ahmed, Hibah M. Aldawsari, Singkome Tima, Hani Z. Asfour, Mohammed W. Al-Rabia, Aya A. Negm, Muhammad H. Sultan, Osama A. A. Madkhali, Nabil A. Alhakamy
Publikováno v:
Pharmaceutics, Vol 12, Iss 6, p 485 (2020)
Flibanserin (FLB) is a multifunctional serotonergic agent that was recently approved by the FDA for the oral treatment of premenopausal women with hypoactive sexual desire disorder. FLB is a centrally acting drug that has a low oral bioavailability o
Externí odkaz:
https://doaj.org/article/9784df45f76740319c3bf62098faf01a
Autor:
Aya A. Negm, Hibah M. Aldawsari
Publikováno v:
Tropical Journal of Pharmaceutical Research. 19:11-15
Purpose: To enhance raloxifene (RLX) delivery and cytotoxicity against breast cancer (MCF-7) cell lines. Methods: This was a solubility study of RLX in different oils, surfactants, and co-surfactants. Twelve formulae were tested to reach the smallest
Autor:
Usama A, Fahmy, Shaimaa M, Badr-Eldin, Osama A A, Ahmed, Hibah M, Aldawsari, Singkome, Tima, Hani Z, Asfour, Mohammed W, Al-Rabia, Aya A, Negm, Muhammad H, Sultan, Osama A A, Madkhali, Nabil A, Alhakamy
Publikováno v:
Pharmaceutics
Flibanserin (FLB) is a multifunctional serotonergic agent that was recently approved by the FDA for the oral treatment of premenopausal women with hypoactive sexual desire disorder. FLB is a centrally acting drug that has a low oral bioavailability o
Autor:
Hibah M. Aldawsari, Nabil A. Alhakamy, Osama Madkhali, Aya A. Negm, Hani Z. Asfour, Mohammed W. Al-Rabia, Muhammad Hadi Sultan, Singkome Tima, Osama A. A. Ahmed, Shaimaa M Badr-Eldin, Usama A. Fahmy
Publikováno v:
Pharmaceutics
Volume 12
Issue 6
Pharmaceutics, Vol 12, Iss 485, p 485 (2020)
Volume 12
Issue 6
Pharmaceutics, Vol 12, Iss 485, p 485 (2020)
Flibanserin (FLB) is a multifunctional serotonergic agent that was recently approved by the FDA for the oral treatment of premenopausal women with hypoactive sexual desire disorder. FLB is a centrally acting drug that has a low oral bioavailability o
Autor:
Fahmy, Usama A.1,2 (AUTHOR) uahmedkauedu.sa@kau.edu.sa, Badr-Eldin, Shaimaa M.1,3 (AUTHOR) oaahmed@kau.edu.sa, Ahmed, Osama A. A.1,2 (AUTHOR) haldosari@kau.edu.sa, Aldawsari, Hibah M.1,4 (AUTHOR) nalhakamy@kau.edu.sa, Tima, Singkome5 (AUTHOR) singkome.tima@cmu.ac.th, Asfour, Hani Z.6 (AUTHOR) hasfour@kau.edu.sa, Al-Rabia, Mohammed W.6 (AUTHOR) mwalrabia@kau.edu.sa, Negm, Aya A.7 (AUTHOR) negma@uwindsor.ca, Sultan, Muhammad H.8 (AUTHOR) mhsultan@jazanu.edu.sa, Madkhali, Osama A. A.8 (AUTHOR) omadkhali@jazanu.edu.sa, Alhakamy, Nabil A.1,2,4,9 (AUTHOR)
Publikováno v:
Pharmaceutics. Feb2024, Vol. 16 Issue 2, p189. 2p.
Autor:
Fahmy, Usama A.1,2 (AUTHOR) uahmedkauedu.sa@kau.edu.sa, Badr-Eldin, Shaimaa M.1,3 (AUTHOR) oaahmed@kau.edu.sa, Ahmed, Osama A. A.1,2 (AUTHOR) haldosari@kau.edu.sa, Aldawsari, Hibah M.1,4 (AUTHOR) nalhakamy@kau.edu.sa, Tima, Singkome5 (AUTHOR) singkome.tima@cmu.ac.th, Asfour, Hani Z.6 (AUTHOR) hasfour@kau.edu.sa, Al-Rabia, Mohammed W.6 (AUTHOR) mwalrabia@kau.edu.sa, Negm, Aya A.7 (AUTHOR) negma@uwindsor.ca, Sultan, Muhammad H.8 (AUTHOR) mhsultan@jazanu.edu.sa, Madkhali, Osama A. A.8 (AUTHOR) omadkhali@jazanu.edu.sa, Alhakamy, Nabil A.1,2,4,9 (AUTHOR)
Publikováno v:
Pharmaceutics. Jun2020, Vol. 12 Issue 6, p485. 1p.
This book discusses basics of brain diseases and the role of nanobiotechnology in existing treatment options for neurodegenerative disorders. It begins with an overview of brain diseases and the need for novel drug-delivery approaches. It highlights